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ABSTRACT
Replication of mitochondrial DNA is strictly regu-
lated during differentiation and development allow-
ing each cell type to acquire its required mtDNA copy
number to meet its specific needs for energy. Undif-
ferentiated cells establish the mtDNA set point, which
provides low numbers of mtDNA copy but sufficient
template for replication once cells commit to specific
lineages. However, cancer cells, such as those from
the human glioblastoma multiforme cell line, HSR-
GBM1, cannot complete differentiation as they fail
to enforce the mtDNA set point and are trapped in
a ‘pseudo-differentiated’ state. Global DNA methyla-
tion is likely to be a major contributing factor, as DNA
demethylation treatments promote differentiation of
HSR-GBM1 cells. To determine the relationship be-
tween DNA methylation and mtDNA copy number
in cancer cells, we applied whole genome MeDIP-
Seq and RNA-Seq to HSR-GBM1 cells and following
their treatment with the DNA demethylation agents 5-
azacytidine and vitamin C. We identified key methy-
lated regions modulated by the DNA demethylation
agents that also induced synchronous changes to
mtDNA copy number and nuclear gene expression.
Our findings highlight the control exerted by DNA
methylation on the expression of key genes, the reg-
ulation of mtDNA copy number and establishment of
the mtDNA set point, which collectively contribute to
tumorigenesis.
INTRODUCTION
The human mitochondrial genome (mitochondrial DNA,
mtDNA) is a circular, double stranded molecule that is
∼16.6 kb in size (1). It is essential for the production of en-
ergy as it encodes 13 subunits of the electron transfer chain
(ETC), which generates the vast majority of cellular energy
through the biochemical process of oxidative phosphoryla-
tion (OXPHOS). mtDNA also encodes 22 transfer RNAs
(tRNAs) and 2 ribosomal RNAs (rRNAs). The major non-
coding region, the D-loop, is the site of interaction for the
nuclear-encoded mtDNA transcription and replication fac-
tors that bind to the mitochondrial genome to regulate mi-
tochondrial genomic processes (1). For example, this region
contains the transcription start sites for the heavy and light
strands of the genome, namely the heavy and light strand
promoters (HSP1/2 and LSP), and the site for the initiation
of heavy strand replication (OH).
Cells possess multiple copies of mtDNA with mtDNA
copy number being cell-type specific. This is achieved dur-
ing early development when mtDNA replication is strictly
regulated in order that a cell acquires the appropriate num-
bers of mtDNA copy to meet its specific functions when
fully differentiated (2,3). They are empowered to do this
as they had previously established the mtDNA set point,
which is defined as the number of mtDNA copies (∼200)
that a naı̈ve cell possesses before it initiates the process of
differentiation. These copies are then used by undifferenti-
ated cells as the template for mtDNA replication as they dif-
ferentiate into distinct mature cell types (2–6). Indeed, dur-
ing differentiation, mtDNA copy number increases in a syn-
chronous manner as cells mature from a naı̈ve state to a fully
differentiated state, which is modulated by the expression
of genes that are the master regulators of differentiation.
They then express genes associated with terminal differen-
tiation and possess their required numbers of mtDNA copy
(4–6). However, a number of cancer cell types are unable to
expand their mtDNA copy number as they mainly rely on
aerobic glycolysis for energy production, which allows for
higher rates of cellular proliferation and prevents differen-
tiation from taking place (4). Indeed, cancer cells appear to
be trapped in a ‘pseudo-differentiated’ state whereby they
are unable to complete differentiation and cannot increase
mtDNA copy number (7,8). As a result, they fail to main-
tain or reinforce the mtDNA set point.
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mtDNA replication is dependent on transcription having
first taken place and is driven by a group of nuclear-encoded
mitochondrial-specific transcription and replication fac-
tors (9,10). There are several key mitochondrial-specific
and direct-binding transcription factors including mito-
chondrial RNA polymerase (POLRMT) (11), mitochon-
drial transcription factor A (TFAM) (12,13) and mitochon-
drial transcription factors B1 (TFB1M) and B2 (TFB2M)
(14). The initiation of replication requires a short tran-
script that is specifically transcribed for mtDNA replication
(15) and is used by the direct-binding mitochondrial spe-
cific DNA Polymerase Gamma (POLG) to drive mtDNA
replication (16,17). In the human, this is a heterotrimer en-
zyme composed of a catalytic subunit (POLGA) and two
accessory subunits (POLGB) (18). POLGA (encoded by
the gene POLG) acts as the DNA polymerase (19) whereas
POLGB (encoded by the gene POLG2) recognizes the ini-
tial RNA primer and enhances the enzymatic activity of
POLG (9,18,20). This process is supported by Twinkle
(TWNK), the DNA helicase that separates the two strands
allowing for replication to take place (21,22), and the mito-
chondrial single-stranded DNA binding protein (SSBP1),
which acts to stabilize the transient status of single-stranded
DNA. Furthermore, the double-stranded circular struc-
ture of the mitochondrial genome ensures the maintenance
of DNA topology during mtDNA replication by allowing
the two strands of the circular genome to unwind or ro-
tate around each other. The mitochondrial topoisomerase,
which is encoded by the TOP1MT gene, can facilitate this
by transiently breaking one strand of mtDNA and religat-
ing the strand after having passed through the other strand
(23).
A group of indirect factors also play vital roles in regulat-
ing mtDNA transcription and replication even though they
do not directly bind to mtDNA as is the case for the direct-
binding factors. The best-characterized regulators are the
nuclear respiratory factors (NRF1 and NRF2), the peroxi-
some proliferator-activated receptor  coactivator-1 family
(PGC1), the Sirtuin family, especially Sirtuin 1 and Sir-
tuin 3, the tumor suppressor p53 and signal transducer and
activator of transcription 3 (STAT3). NRFs interact with
PGC1 cofactors to regulate the expression of TFB1M and
TFB2M by binding to their promoter regions (24). In ad-
dition, Sirtuin1 and 3, NAD+-dependent deacetylases en-
coded by the SIRT1/3 genes, are co-factors with PGC1
that co-localise with TFAM inside mitochondria (25,26).
Given that thyroid hormone T3 is essential for mitochon-
drial biogenesis (27), it has been shown that T3 binding
to T3 receptors affects mtDNA expression by either bind-
ing to mtDNA directly or interfering with the expression of
the transcription factors in the nucleus, such as NRF1 and
PCG1 (28–31).
We have previously shown that mtDNA copy number
is associated with DNA methylation at exon 2 of POLG
(4,32). It appears that tumor cells are extensively DNA
methylated, which normally occurs at CpG dinucleotides,
and converts the cytosine into 5-methylcytosine (5mC)
(33,34). The glioblastoma multiforme HSR-GBM1 cell line
is a high-grade malignant glioblastoma cell line (35). It
is DNA hypermethylated, which is associated with onco-
mutations of the isocitrate dehydrogenase (IDH1/2) in the
citric acid cycle (33,36–39). The hypermethylated genome,
which leads to and supports its tumorigenic gene profile
(37–41), can be reversed through the use of DNA demethy-
lation agents such as 5-azacytidine (5Aza) and vitamin C
(VitC) (42,43). 5Aza is a chemical analogue of cytosine that
inhibits DNA methylation at low concentrations, and has
been applied in cancer therapies (43,44). It blocks the DNA
methyltransferase, DNMT1, which causes global DNA
demethylation (45). VitC can also induce DNA demethy-
lation by enhancing the activity of the TET1 enzyme and,
thus, improves the conversion of 5mC to the DNA demethy-
lated state of 5-hydroxy-methylcytosine (5hmC) (42).
The demethylation of HSR-GBM1 cells results in signif-
icant increases in mtDNA copy number, as they are able to
modulate mtDNA copy number in synchrony with changes
in chromosomal gene expression patterns during differenti-
ation (4,6). Indeed, during development, the DNA methy-
lation status of the genome undergoes significant changes
to firstly erase the parental profiles by ten-eleven translo-
cation methylcytosine dioxygenases, the TET family, and
reestablish their own profiles through the DNA methyl-
transferase (DNMT) family of genes during differentiation
(46,47). This highlights the cooperation that exists between
the two genomes and the importance of the collective reg-
ulation of DNA methylation and mtDNA copy number in
tumorigenesis and differentiation.
To further investigate the impact of DNA methylation
on regulating the mtDNA-specific transcription and repli-
cation factors, we have used methylated DNA immunopre-
cipitation (MeDIP) in combination with whole-genome se-
quencing (MeDIP-Seq), whole genome RNA-sequencing
(RNA-Seq), and a custom designed high-throughput Flu-
idigm real-time PCR array on the well characterised HSR-
GBM1 tumor cell line and compared its DNA methyla-
tion profiles to its demethylated state when induced by 5Aza
and VitC. Our results show that a number of tumor-specific
genes and several key mtDNA transcription and replication
factors are modulated by global DNA demethylation.
MATERIALS AND METHODS
Cell culture
HSR-GBM1 cells were cultured as neurospheres on ultra-
low attachment plates (Sigma-Aldrich, MO, USA) in
Dulbecco’s Modified Eagle Medium /Nutrient Mixture
(DMEM/F-12) Media (Thermo Fisher Scientific, MA,
USA) containing 2% StemPro neural supplement (Thermo
Fisher Scientific), 20 ng/ml basic fibroblast growth factor
(bFGF; Merck Millipore, MO, USA) and 20 ng/ml epi-
dermal growth factor (EGF; Merck Millipore) at 37◦C, 5%
CO2 and 95% humidity.
DNA demethylation assay
To induce DNA demethylation, HSR-GBM1 cells were cul-
tured in the presence of 0.5 M of 5Aza (Sigma-Aldrich) for
48 h or 100 g/ml of VitC (L-ascorbic acid, Sigma-Aldrich)
for 72 h. Culture media was changed every 24 h. Cells were
harvested after the treatments for downstream experiments
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DNA and RNA extraction
Total genomic DNA and RNA were extracted from cul-
tured cell pellets using the ISOLATE II Genomic DNA Kit
(Bioline, London, UK) and RNeasy Mini Kit (Qiagen, CA,
USA), respectively, according to the manufacturer’s pro-
tocols with minor modifications. The DNA samples were
treated with 3 l of RNase solution (Qiagen) and Proteinase
K Solution (20 g/l; Qiagen) at 65◦C for 10 min and the
RNA samples were treated with DNase I (3 kunitz units/
l; Qiagen) for 20 min.
Determination of mtDNA copy number per cell
mtDNA copy number per cell was determined using an es-
tablished protocol, as previously described (4). Quantita-
tive real-time PCR (qPCR) was performed on purified total
DNA targeting β-globin and mtDNA using a Rotor-Gene
3000 (Corbett Research, Cambridge, UK). mtDNA copy
number was calculated using the formula: mtDNA copy
number per cell = 2 × NmtDNA/N-globin, where NmtDNA
and N-globin, determined by the formula: N = (qPCR prod-
uct concentration × 6.023 × 1014)/(qPCR product size in
bp × 660), as described in (32). The concentration of the
qPCR product is determined using standard curves. Primer
sequences and reaction conditions are listed in Supplemen-
tary Table S1. Biological triplicates (n = 3) were analysed.
Immunoprecipitation of methylated DNA (MeDIP)
Five microgram of genomic DNA was sheared into 200–
1000 bp fragments in a precooled and degassed Covaris
Adaptive Focused Acoustics (AFA™) S220 system. The ds-
DNA was denatured by incubation at 95◦C for 10 min and
then underwent MeDIP, as described in (48). 1.5 g of anti-
5mC antibody (Active Motif) were added to 3 g of DNA
fragments and 20 l per sample of Dynabeads® Protein G
(Thermo Fisher Scientific) in 500 l of 1× IP buffer (100
mM sodium phosphate, pH 7.0; 1.4 M NaCl; 0.5% Tri-
ton X-100) at 4◦C for 16 h under rotation. The beads were
washed with 1 ml of 1× IP buffer three times and were re-
suspended in 250 l proteinase K digestion buffer (50 mM
Tris–HCl, pH 8.0; 10 M EDTA, pH 8.0; 1.0% SDS) with 10
l of proteinase K (20 mg/ml; Bioline) at 50◦C for 3 h on
a thermo-shaker. The supernatant was then collected into
a new tube and placed on a magnetic particle concentra-
tor (Thermo Fisher Scientific). DNA was purified from the
elutant using the QIAquick PCR Purification Kit (Qiagen).
Purified DNA was eluted in 50 l of autoclaved Milli-Q
H2O.
MeDIP-Seq
To adapt MeDIP for next generation sequencing, mi-
nor changes were made to the MeDIP procedure de-
scribed above. Two microgram of each genomic DNA sam-
ple were sheared into ∼500 bp in a precooled and degassed
Covaris Adaptive Focused Acoustics (AFA™) S220 sys-
tem. These fragments were then end repaired, A-tailed, lig-
ated to Illumina adaptors (including the sample specific in-
dexed) and purified without amplification to ensure conser-
vation of methylated CpGs using the Illumina TruSeq DNA
PCR-Free Kit, as described in the manufacturer’s Low
Sample (LS) protocol (Illumina Protocol part #15036187
Rev A Jan 2013). The dsDNA libraries then followed the
procedure, as described above. After MeDIP, dsDNA li-
braries were generated and amplified for 10 cycles, as per
the TruSeq ChIPSeq protocol with standard Illumina P7
and P5 primers (Illumina protocol part #15023092 Rev A
August 2012). The resultant libraries were analysed using
Qubit (Agilent) and Bioanalyzer (ThermoFisher Scientific)
and quantitated by qPCR. The 12 pM library pool was
prepared based upon qPCR and used for clustering by the
cBot™ Hybridization system (Illumina, CA, USA). Clus-
ter generation was performed according to the cBot™ user
guide (part #15006165 Rev K October 2012). Clusters
were in the optimal range (795 k/mm2; optimal 750–900
k/mm2). 50-bp single-read sequencing was then performed
on the Illumina HiSeq1500 and HiSeq3000 sequencing plat-
forms using the Illumina protocol (15035788 Rev D, April
2014; 15066493 v01, August 2015). The reads were con-
verted to fastq format and adaptors were removed using
the bcl2fastq software (Illumina). The number of reads per
sample was evenly distributed. In total, >550 million reads
passed the filter, and over 95% of the sequencing reads
passed the Illumina sequencing quality score of Q30 that
was deemed excellent quality for base-calling. Run qual-
ity parameters were deemed excellent with the PhiX spike-
in having an error rate of < 0.2% (expected < 0.5%) and
phasing/prephasing of < 0.08/0.1 (expected 0.2/< 0.4).
Bioinformatics analysis for MeDIP-Seq
Sequencing files in fastq format firstly underwent and
passed the pre-alignment quality and remaining adaptor
check using the FastQC software (v 0.11.5; down-
loaded from Babraham Bioinformatics public projects
https://www.bioinformatics.babraham.ac.uk/projects/).
The raw sequences were then mapped to the human
reference genome GRCh38/hg38 (UCSC) using the
Burrows-Wheeler Aligner (BWA) software (version
0.7.16a) (49). The commands of ‘aln’ and ‘samse’ of the
BWA-backtrack algorithm were used with their default
settings to undertake the mapping. The output files (*.sam)
were then combined, filtered and converted to bam files
(*.bam) by Samtools (version 1.4) using the commands of
‘view’, ‘sort’ and ‘merge’. Further filtering based on the
mapping scores (MAPQ ≥ 30) was performed to remove
ambiguous reads and only uniquely mapped reads were
kept for further analysis. Mapping files (*.bam) were
exported for downstream analysis. Mapping parameters
are listed in Supplementary Table S2.
Analytical analysis was carried out using the MEDIPS
package (version 1.24.0) on R programming software (ver-
sion 3.3.2) (50,51). Command codes were based on the R
script document of MEDIPS. MeDIP-Seq specific qual-
ity control analysis was performed on the mapping files
for each sample, which included saturation analysis, CpG
coverage analysis and CpG enrichment analysis. The pa-
rameters specified in this analysis were set to: ‘extend’ of
500, which means all short reads were extended to 500 nu-
cleotides according to the reference genome; ‘shift’ to 0,
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for the sequences; ‘window size’ to 100, which indicates the
analysis was performed every 100 bp of the genome; ‘uniq’
to 1, which indicates that the reads that mapped to ex-
actly the same genomic positions were counted as one read.
A coupling factor was set up based on the HSR-GBM1
samples (control group) for normalization. Biological tripli-
cates were grouped into three cohorts: the GBM cohort, the
GBM + VitC cohort and the GBM + 5Aza cohort. Differ-
entially methylated windows of 100 bp were identified be-
tween groups using the ‘edgeR’ plug-in function. Among
the six samples in each comparison, genomic windows that
were covered by a minimal counts threshold of 100 reads
were kept for further statistical analysis (minsrowsum =
100). Statistically significant results were selected using cri-
teria for the adjusted P value ≤ 0.05. Continuous signifi-
cant windows were merged as one differentially methylated
region (DMR).
Comparisons between the GBM cohort and the GBM
+ VitC cohort and between the GBM cohort and the
GBM + 5Aza cohort were performed. DMRs identified
between the cohorts then underwent annotation based on
their corresponding regions in the human genome (hg38)
using the ChIPSeeker package (version 3.5) (52). The built-
in function of region of interest (ROI) analysis in the
MEDIPS package was specifically used to investigate the
DNA methylation levels at the CpG islands (CGIs) found
in gene bodies and promoter regions of the mtDNA repli-
cation factors. One-way ANOVA was used to statistically
compare the mean relative methylation score of ROIs.
Relative methylation score was developed specifically for
MeDIP-Seq in order to normalize methylation scores for
regions based on the concept of CpG coupling analysis
(50,51). Relative methylation score is calculated using the
formula of log 2 (mean MeDIP-Seq signal × 106/the corre-
sponding estimated number of reads based on the coupling
analysis × the total number of short reads) (50). It has been
shown to correlate well with DNA methylation levels fol-
lowing bisulfite conversion methods, when applied to indi-
vidual CpG sites within a region (50). In other words, rel-
ative methylation score offers a relatively high-throughput
and accurate measurement of DNA methylation.
Purification of mtDNA from cells
To further verify whether DNA methylation exists within
the mitochondrial genome, mtDNA was purified from cells
to eliminate mtDNA pseudo-genes present in the nuclear
genome from the analysis. Mitochondrial isolation was per-
formed using a 5 ml Potter-Elvehjem tissue grinder set (Cat.
No. 358034; Wheaton, USA). Freshly collected cells (∼10
million) were resuspended in 5 ml of solution A (20 mM
HEPES–KOH, pH 7.6, 220 mM Mannitol, 70 mM su-
crose, 1 mM EDTA and 2 mg/ml BSA freshly added) and
placed on ice for 15 min to facilitate swelling. The cells were
then homogenized at 4◦C in a glass chamber with a drill-
fitted pestle for 50 repetitions. The cell homogenate was cen-
trifuged at 800g for 10 min to remove cell debris and nuclei.
The supernatant was centrifuged at 10 000 g for 20 min to
pellet the mitochondrial fraction. The pellet was then resus-
pended in 175 l of solution B (20 mM HEPES–KOH, pH
7.6, 220 mM Mannitol, 70 mM sucrose, 10 mM MgCl2).
10 l of DNase I (3 kunitz units/l; Qiagen) in 20 l of
RDD buffer (Qiagen) were added to the mitochondrial sus-
pension and incubated at 37◦C for 30 min to further remove
nuclear DNA. 1 ml of solution A without BSA was added
to stop DNase activity and the suspension was centrifuged
at 10 500 g for 20 min at 4◦C to pellet the mitochondria.
The pellet of mitochondria was resuspended in 200 l of
lysis buffer (50 mM Tris–HCl, pH 8.0, 10 mM EDTA and
1% SDS) with 1 l of proteinase K (20 mg/ml, Bioline) and
incubated at 50◦C for 60 min. mtDNA was then purified us-
ing the phenol:chloroform method by adding 1 volume of
phenol: chloroform: isoamyl alcohol (25:24:1, Sigma), vor-
texing for 1 min and centrifuging at 17 000g for 5 min. The
upper layer was collected and underwent another round of
chloroform extraction by adding 1 volume of chloroform:
isoamyl alcohol (24:1, Sigma). The upper layer was col-
lected and mtDNA was precipitated by adding 2.5 volumes
of 100% ethanol, 0.1 volume of 3 M sodium acetate and 1
l of glycogen (20 g/l), and incubated at −80◦C for at
least 2 h. Samples were centrifuged at 20 000g for 10 min
at 4◦C and the mtDNA pellets were washed with 500 l of
70% ethanol. After further centrifugation at 12 000g for 5
min at 4◦C, the mtDNA pellets were air-dried for 10 min
and dissolved in 50 l of autoclaved Milli-Q H2O.
Purified mtDNA samples firstly underwent the MeDIP-
long-PCR protocol without sonication to demonstrate the
presence of DNA methylation on mtDNA (described be-
low in the section entitled ‘Whole-mtDNA MeDIP and
amplification by long PCR’). Secondly, purified mtDNA
samples and long PCR products underwent MeDIP (with
sonication) followed by qPCR to determine the levels of
DNA methylation at different regions of the mitochondrial
genome (described below in the section entitled ‘Quantifi-
cation of MeDIP products’).
Whole-mtDNA MeDIP and amplification by long PCR
Prior to performing MeDIP, a positive and a negative con-
trol were generated by long PCR to generate two over-
lapping long mtDNA fragments (∼8500 bp) spanning the
whole mitochondrial genome. As PCR products are deemed
to be unmethylated, the negative control (Neg-longPCR-
5mC) comprised equal concentrations of two long mtDNA
fragments generated by long PCR using primer set 1 (Sup-
plementary Table S1). Each long PCR contained 1× High
Fidelity PCR buffer, 100 mM MgSO4, 1 mM dNTPs (Bi-
oline), 1 U of Platinum Taq High Fidelity (Invitrogen), 10
M each forward and reverse primer (primer set 1; Sup-
plementary Table S1) in a total volume of 50 l. Reaction
cycling profiles were 94◦C for 2 min, 35 cycles of 94◦C for
15 s, 63◦C for 30 s and 68◦C for 8 min 45 s. Similarly, the
positive control (Pos-longPCR-5mC) comprised equal con-
centrations of the two long mtDNA fragments that had
undergone DNA methylation treatment. DNA methylation
treatment was carried out using the CpG methyltransferase
M.SssI (New England Biolabs; USA), according to the
manufacturer’s instructions. Briefly, 1 g of the combined
mtDNA fragments was incubated with four units of the
enzyme in the presence of 160 M S-adenosylmethionine
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The purified mtDNA sample (mtDNA-5mC), and the
positive (Pos-longPCR-5mC) and negative (Neg-longPCR-
5mC) control samples then underwent MeDIP, as described
in the section of ‘Immunoprecipitation of methylated DNA
(MeDIP)’, except that the sonication step was not included.
This maintains the integrity of the mtDNA, which acts as
the template for long PCR following MeDIP. Moreover, the
purified mtDNA sample also underwent MeDIP without
5mC antibody (mtDNA-NAC) to account for non-specific
pull-down. MeDIP products were purified using the phe-
nol:chloroform method, and assessed by long PCR using
primer set 2 (Supplementary Table S1) with the same re-
action conditions, as described above. mtDNA sequences
targeted by primer set 2 are located just downstream and
just upstream of 5′ and 3′ ends of the sequences used for the
negative and positive controls, respectively. A total DNA
sample isolated from GBM cells (Total DNA) and a non-
template control (H2O; NTC) were also amplified. PCR
products were then run on a 0.8% agarose gel.
Quantification of MeDIP products
After performing MeDIP (with a sonication step), as de-
scribed in the section ‘Immunoprecipitation of methylated
DNA (MeDIP)’, on the purified mtDNA samples and long
PCR products, the levels of DNA methylation for the re-
gions of interest were quantified by qPCR on a Rotor-Gene
3000 machine under primer specific conditions (Supple-
mentary Table S1). The levels of DNA methylation for the
mitochondrial genome were determined by firstly normal-
izing the qPCR signals of the MeDIP products to their cor-
responding input samples (5mC/Input), and then weight-
ing these values against the positive and negative controls
that were used to represent 100% and 0% levels of DNA
methylation, respectively. The levels of DNA methylation at
exon 2 of POLG, and TOP1MT exon 8 and intron 10 from
MeDIP-Seq were also validated by MeDIP-qPCR using to-
tal DNA. The results were determined by normalizing the
qPCR signals of the MeDIP products to their correspond-
ing input samples (5mC/Input).
Determination of copy number variation (CNV)
All samples were genotyped for CNV using the Illu-
mina Human Global Screening Array Beadchip (Illumina),
which covers ∼700K SNPs. Array data were processed us-
ing GenomeStudio 2.0 (Illumina), according to the user’s
manual. Data normalization, clustering and genotype call-
ing were performed using the Genotype Module. The full
data report containing log R ratios (LRR) and B allele
frequencies (BAF) for each probe was then exported as
input data to the Nexus 9.0 software (Biodiscovery Inc.,
CA, USA) for advanced analysis. The Nexus Copy Num-
ber Module was used to carry out the comparisons of DNA
copy number between groups. Human genome build hg19
was chosen as the reference genome to assign genome loca-
tions. Statistical significance between groups in individual
SNPs was determined by P value ≤ 0.05. Genomic regions
were aligned to hg38 for overlapping analysis with DMRs.
RNA-Seq analysis
Total RNA was submitted to the Australian Genome Re-
search Facility (AGRF; VIC, Australia) to perform RNA
sequencing. An Agilent Bioanalysor Nanochip (Agilent)
was used to determine the integrity of the RNA samples.
cDNA libraries were constructed using the Illumina Truseq
Standard mRNA Kit (Illumina), according to the man-
ufacturer’s instructions. The libraries were sequenced on
the HiSeq 2500 platform (Illumina). Image analysis was
performed in real time using the HiSeq Control Software
(HCS) v2.2.68 and Real Time Analysis (RTA) program
v1.18.66.3 running on the instrument’s computer. RTA per-
formed real-time base calling on the HiSeq instrument com-
puter. The Illumina bcl2fastq 2.19.0.316 pipeline was then
used to generate the sequence data at AGRF. The sequences
were mapped to human genome hg38 by STAR aligner
(2.5.3a) using default settings (53). The annotation was
based on the comprehensive GENCODE gene annotation
(v26). Only the uniquely mapped reads were used for down-
stream analysis. The reads were then summarized to counts
for each gene by the ‘featureCounts’ function in the Rsub-
read package (1.26.0) using the inbuilt annotation hg38
(54). Identification of differentially expressed genes was per-
formed using the edgeR package (3.16.5) employing the
trimmed mean of M-values normalization method (TMM)
application (55,56). Gene expression data were uploaded to
Ingenuity Pathway Analysis software (IPA; Qiagen). Genes
with false discovery rate (FDR) ≤0.05 and absolute fold
change ≥ 2 were deemed to be significantly differentially
expressed genes. These genes were used to perform path-
way analysis for determining the most affected canonical
pathways, biological functions and networks, and used for
undertaking the DMR-overlapping analysis.
Gene expression analysis using the Fluidigm platform
cDNA was synthesized from 1 g of total RNA using oligo
(dT) primers and the Superscript III First-Strand synthesis
system (Thermo Fisher Scientific), according to the manu-
facturer’s instructions. Pre-amplification was performed to
increase the number of copies of each gene to detectable lev-
els, as detailed in Gene Expression Preamp with the Flu-
idigm Preamp MasterMix and Taqman Assays Quick Ref-
erence PN 100-5876 B1. All Taqman assays are listed in
Supplementary Table S3. Taqman assays were pooled with
C1 DNA suspension buffer to produce a final concentration
for each assay of 180 nM. 1.25 l of each cDNA sample as
well as a non-template control underwent pre-amplification
for 14 cycles with 3.75 l of the pooled assays and Taqman
PreAmp Master mix (Thermo Fisher Scientific), according
to the manufacturer’s instructions.
Following preamplification, reaction products were di-
luted 5-fold in C1 DNA suspension buffer. Assays and sam-
ples were combined in a 96.96 Dynamic array IFC plate, ac-
cording to the Fluidigm® 96.96 Real-Time PCR Workflow
Quick Reference PN 6800088. An Integrated Fluidic Circuit
(IFC) controller HX was used to prime and load the plate.
5 l of each preamplified sample were loaded in duplicate
into each sample inlet and 5 l of each Taqman assay (10×)
were also loaded into each assay inlet of the plate. Gene ex-
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Standard v2 protocol. Data were exported as a spreadsheet
(.csv) using the Fluidigm Real-Time PCR analysis software
(v4.1.1). Differentially expressed genes were analysed using
the HTqPCR package (version 1.28) (57). The package uses
the ‘deltaCt’ method of normalization. To improve the anal-
ysis, three housekeeping genes were used for normalization.
ActB, HPRT1 and OAZ1 were chosen as the housekeeping
genes for the nuclear genes. They are widely used in glioblas-
toma studies (4,58). Rn18S, HPRT1 and OAZ1 were cho-
sen as the housekeeping genes for the mitochondrial-related
genes. Rn18S has higher levels of expression and is, there-
fore, more suitable for the normalization of the mitochon-
drial genes, which have much higher levels of expression
than nuclear-encoded genes (58,59). The package uses the
‘limma’ method to perform statistical analysis, as stated in
the user guide available from the website. Results were then
exported and plotted using GraphPad Prism 7 (GraphPad
Software, Inc., CA, USA).
Data deposition
MeDIP-Seq sequences (triplicates) for the HSR-GBM1
cells and HSR-GBM1 cells treated with 5Aza and VitC have
been deposited in the Sequence Read Archive (SRA) un-
der accession number SRP080899. CNV data and RNA se-
quencing data have been deposited in the Gene Expression
Omnibus (GEO) under accession number GSE98693.
RESULTS
Whole genome MeDIP-Seq, quality control and CNV anal-
ysis
To investigate the impact that DNA methylation has on
the whole genome and how it affects mtDNA replication,
we performed whole genome MeDIP-Seq on DNA sam-
ples from HSR-GBM1 cells (GBM) to identify sites that are
DNA methylated, in order to then compare them with the
DNA methylome of HSR-GBM1 cells cultured with either
5Aza (GBM + 5Aza) or VitC (GBM + VitC) to determine
which sites undergo modulation. The HSR-GBM1 cell line
was chosen as it is one of the best-characterized GBM cell
lines and is indicative of an undifferentiated cancer cell line,
which has the potential to be differentiated into neuronal-
and astrocyte-like cells (6,35) once it has undergone DNA
demethylation induced by 5Aza or VitC (4).
On average, >40.4 million uniquely mapped sequences
per sample were obtained (Table 1). The mapped reads were
cleaned to remove duplicates that mapped to exactly the
same genomic position and were counted as one read to
ensure that the repeat reads resulting from PCR amplifica-
tion were not biasing the data. To check the reproducibility
of the workflow, a Pearson correlation test was performed
on the mapped reads within each cohort. On average, high
correlation scores (0.94 for the GBM cohort, 0.95 for the
GBM + VitC cohort and 0.95 for the GBM + 5Aza cohort)
were achieved amongst the triplicates for each cohort (Ta-
ble 1). The MEDIPS analysis package offers several quality
control tests for MeDIP-Seq experiments. Saturation anal-
ysis gives the estimated saturation correlation score to as-
sess the coverage of the genome. Overall, scores of 0.95
were achieved from the samples, which indicates sufficient
coverage (Table 1). CpG coverage analysis specifically in-
cludes coverage levels of the 28 million CpG dinucleotides
in the human genome. On average, >91% of total CpG din-
ucleotides in the human genome were covered with at least
one read which indicates good enrichment of the targets for
downstream analysis (Table 1) and the differences in cover-
age depth are shown in Supplementary Figure S1.
Cancer cells frequently exhibit genomic instability. CNVs
between cohorts can have a direct impact on MeDIP-Seq
signals that are not reflective of true changes in DNA
methylation and, therefore, result in false positive or nega-
tive results (60). To preclude the potential impact of CNVs
on the MeDIP-Seq data, the three cohorts of cells were
genotyped to screen for CNVs over the whole genome. By
using an Illumina global screening array, 700 K SNPs were
analyzed and statistical comparisons were performed us-
ing the Nexus 9.0 Copy Number module. Overall gains in
copy number were observed in the GBM genome. In all, 247
regions were identified as copy number gains (Supplemen-
tary Table S4). However, no significant CNVs were identi-
fied between either the GBM and GBM + VitC or GBM +
5Aza cohorts (Supplementary Figure S2). In other words,
the DNA demethylation treatments did not improve or in-
tensify genomic instability among the cohorts of GBM cells,
which means that the CNVs did not impact on the analysis
by MeDIP-Seq.
Identification of differentially methylated regions (DMRs)
Using the MEDIPS package, 816 differentially methylated
regions (DMRs) were identified between the GBM + 5Aza
and the GBM cohorts and 1743 DMRs between the GBM
+ VitC and GBM cohorts (adjusted P value ≤ 0.05, min-
rowsum ≥ 100). The heatmap for the total number of
DMRs indicated that the two cohorts that had under-
gone DNA demethylation treatment exhibited significant
changes when compared with the GBM methylome (Figure
1A). Interestingly, both the GBM + 5Aza and the GBM
+ VitC cohorts exhibited hyper-DMRs and hypo-DMRs
throughout the genome (Figure 1A). Indeed, 316 out of 816
DMRs (38.72%) were identified to be demethylated by 5Aza
and 500 out of 1743 DMRs (28.68%) were demethylated by
VitC. The occurrence of hypermethylation is expected, es-
pecially in the GBM + VitC cohort, as the rebound effect
can result in the re-establishment of DNA methylation (4).
We focused on the demethylated DMRs for further analy-
sis, as they are indicative of the direct effects of the DNA
demethylation treatments.
Between the two cohorts of DMRs, 167 DMRs identi-
fied from the comparison between the GBM + 5Aza cohort
and the GBM cohort were found to overlap with 170 DMRs
identified from the comparison between GBM + VitC and
GBM cohorts (the unequal distribution of DMRs is due to
each of the treatments differentially affecting different re-
gions resulting in some partial overlap) (Figure 1B). In all,
149 DMRs were uniquely identified from the comparison
between the GBM + 5Aza and the GBM cohorts, whereas
330 DMRs were uniquely identified from the comparison
between the GBM + VitC and the GBM cohorts (Figure
1B). The uniquely identified DMRs probably resulted from
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Correlation CpGs covered by the reads
GBM 1 41.8 0.95 91.7%
GBM 2 37.3 0.94 0.95 91.51%
GBM 3 38.3 0.95 91.65%
GBM+5Aza 1 37.6 0.95 91.23%
GBM+5Aza 2 45.6 0.95 0.95 91.98%
GBM+5Aza 3 48.6 0.95 92.1%
GBM+VitC 1 37.8 0.95 90.8%
GBM+VitC 2 44.4 0.95 0.95 90.83%
GBM+VitC 3 32.5 0.94 89.56%
Figure 1. Overview of the DMRs. (A) Heatmap of the DNA methylation profiles. Total identified DMRs were plotted using values in counts for the three
biological replicates from the GBM cohort, the GBM + 5Aza cohort and the GBM + VitC cohort. The colour scheme from blue, yellow to red represents
the level of DNA methylation from low to high. (B) Venn diagram of the DMRs identified in the two comparisons. The 316 DMRs identified in the
comparison between GBM + 5Aza and GBM are shown in the blue circle; the 500 DMRs identified between GBM + VitC and GBM are shown in the red
circle. 167 DMRs identified in the GBM + 5Aza cohort overlap or partially overlap with 170 DMRs identified in the GBM + VitC cohort.
demethylation. As a result, the unique DMRs are likely to
be the sites that were only affected by one of the agents.
On the other hand, both of the agents could have demethy-
lated the same DNA region but only one of them was able
to significantly demethylate that region or maintain DNA
demethylation.
As the function of DNA methylation varies dependent
on the location of the methylated sites, the identified DMRs
were then annotated according to their genome location us-
ing the ChIPSeeker package, which identified promoter re-
gions (1000 bp upstream of transcription start site (TSS)),
exons, introns, three UTRs and downstream regions (< 3
kb). These regions are collectively referred to as intragenic
regions and are normally associated with transcriptional
functions. However, the other DMRs (> 50%) are located
at intergenic regions, which refer to non-coding genomic re-
gions between genes (Supplementary Figure S3). Regard-
less of the number of DMRs, it appeared that VitC had
a tendency to affect more intragenic regions when com-
pared with 5Aza. This could arise from the enhanced activ-
ity of the TET1 enzyme modulated by VitC, as it is known
to specifically target more intragenic regions (42), while
DNMT1 is more likely to be inhibited by 5Aza (43), thus
causing global DNA demethylation.
Furthermore, of the DMRs identified, only seven
mapped with the copy number gain regions identified above,
which further suggests the regions possessing CNVs were
not affected by DNA demethylation and had only a very
limited effect on the identification of DMRs (Supplemen-
tary Table S4).
Identification of differentially expressed genes and the asso-
ciation with the DMRs
To investigate the changes to the overall gene expression
profiles induced by DNA demethylation, total RNA sam-
ples from the three cohorts were sequenced and the total
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Figure 2. Overview of differentially expressed genes. (A) Heatmap of the RNA-Seq profiles. Total identified differentially expressed genes (FDR ≤ 0.05,
absolute logFC ≥ 1) for the GBM + 5Aza cohort and the GBM + VitC cohort were plotted based on the fold changes (log2) of read counts for the mean
value of the GBM cohort. The color scheme from blue, yellow to red represents the level of expression from low to high. (B) MDS plot of the RNA profiles
of the three cohorts. The MDS plot shows the similarity of the cohorts for each group indicated by the distance on the first two dimensions. Dimension 1
accounts for 83% of the total variance, and Dimension 2 accounts for 12% of the total variance. The GBM cohort was plotted in green, the GBM + VitC
cohort was plotted in orange and the GBM + 5Aza cohort was plotted in blue. (C) Venn diagram of the differentially expressed genes identified in the two
comparisons. 736 genes identified to be differentially expressed in the comparison between GBM + 5Aza and GBM are shown in the blue circle; 726 genes
identified to be differentially expressed between GBM + VitC and GBM are shown in the red circle. 453 genes overlapped between these two comparisons.
A 42% up-regulation and a 58% down-regulation were identified in both comparisons.
≥ 1) profiles are shown in the heatmap (fold change of
counts in log2 scale) for each of the triplicates from the
treated cohorts (Figure 2A). The multidimensional scal-
ing (MDS) plot analysis shows that the three cohorts are
distinct from each other (Figure 2B). The first dimension
separated the untreated GBM and the DNA demethylated
GBM cohorts, which indicates the primary factor that dis-
tinguishes the cohorts is their DNA methylation status. The
differences between the GBM + 5Aza cohort and GBM +
VitC cohort were also indicated by distance in the second
dimension, which suggests that these two treatments caused
different responses in gene expression despite the effects
of DNA demethylation. Using edgeR for further analysis,
726 differentially expressed genes were identified from the
GBM + VitC cohort and 736 differentially expressed genes
were identified from the GBM + 5Aza cohort (FDR ≤ 0.05
and absolute logFC ≥ 1; Figure 2C). A total of 453 genes
were commonly modulated by both treatments (Figure 2C).
However, 273 genes were uniquely identified in the GBM +
VitC gene list, whereas 283 genes were uniquely modulated
by 5Aza (Figure 2C). Interestingly, both comparisons deter-
mined that 42% of genes were up-regulated and 58% were
down-regulated (Figure 2C), which highlights the dual ef-
fects that DNA methylation has on transcription.
Differentially expressed genes were then used for path-
way analysis using IPA software. The top canonical path-
ways, top diseases and bio-functions affected by each of
the treatments are listed in Table 2. In the top canonical
pathways, hepatic fibrosis and acute phase response signal-
ing pathways were identified in both comparisons, which
suggests the genes in these pathways are greatly sensitive
to DNA demethylation. On the other hand, VitC modu-
lated cellular pathways involved in cellular organization and
cell cycle, including mitotic roles of the polo-like kinase,
and G2/DNA damage checkpoints in cell cycle, whereas
5Aza modulated pathways associated with tumorigenesis
and metabolism including colorectal cancer metastasis sig-
naling, Wnt/-catenin signaling and MIF regulation of in-
nate immunity. The most affected disease was cancer re-
sulting from both treatments with 565 molecules being af-
fected by VitC and 572 molecules affected by 5Aza. Inter-
estingly, VitC tended to modulate cell growth by affecting
DNA replication, recombination, and repair in the cell cy-
cle and triggering cell death, whereas 5Aza tended to inhibit
cellular proliferation. Indeed, the increases in cell number
during tissue culture were slightly lower in the treated co-
horts than the GBM cohort. From the same initial number
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Table 2. Pathways affected by differentially expressed genes (FDR ≤ 0.05, absolute fold change ≥ 2)
Name P-value Overlap/no. of molecules
Top canonical pathways affected by VitC
Hepatic Fibrosis/Hepatic Stellate Cell Activation 5.61E–06 9.8% 18/183
Mitotic Roles of Polo-Like Kinase 1.05E–04 13.6% 9/66
Acute Phase Response Signaling 3.73E–04 8.3% 14/169
Cell Cycle: G2/M DNA Damage Checkpoint Regulation 4.59E–04 14.3% 7/49
Salvage Pathways of Pyrimidine Ribonucleotides 1.60E–03 9.5% 9/95
Diseases and disorders affected by VitC
Cancer 2.57E–04–3.31E–16 565
Organismal Injury and Abnormalities 2.62E–04–3.31E–16 582
Reproductive System Disease 2.24E–04–3.53E–16 333
Gastrointestinal Disease 2.62E–04–4.33E–13 499
Dermatological Diseases and Conditions 1.01E–04–9.62E–11 380
Molecular and cellular functions affected by VitC
Cellular Assembly and Organization 2.68E–04–2.88E–14 122
DNA Replication, Recombination, and Repair 2.68E–04–2.88E–14 41
Cell Cycle 2.14E–04–5.22E–13 104
Cell Death and Survival 2.62E–04–2.84E–12 223
Cellular Movement 2.32E–04–3.75E–12 172
Top canonical pathways affected by 5Aza
Hepatic Fibrosis / Hepatic Stellate Cell Activation 7.52E–15 16.4% 30/183
Colorectal Cancer Metastasis Signaling 8.45E–06 8.5% 21/247
Acute Phase Response Signaling 2.68E–05 9.5% 16/169
Wnt/-catenin Signaling 9.92E–05 8.9% 15/169
MIF Regulation of Innate Immunity 1.39E–04 17.1% 7/41
Diseases and disorders affected by 5Aza
Cancer 2.38E–05–2.97E–22 572
Organismal Injury and Abnormalities 2.38E–05–2.97E–22 585
Dermatological Diseases and Conditions 4.48E–08–2.42E–19 399
Gastrointestinal Disease 1.18E–05–2.84E–18 510
Metabolic Disease 1.68E–05–1.05E–12 139
Molecular and cellular functions affected by 5Aza
Cellular Movement 2.39E–05–5.26E–18 173
Cellular Development 2.30E–05–2.14E–10 219
Cellular Growth and Proliferation 2.30E–05–2.14E-10 206
Cell Morphology 1.94E-05–5.13E-10 176
Lipid Metabolism 2.18E–05–6.79E–10 88
GBM+VitC gained 2.5 (± 0.14) fold and GBM + 5Aza
gained 2.55 (± 0.1) fold (P > 0.05). The networks analyses
described the gene ontology (GO) enrichment for the dif-
ferentially expressed genes (Supplementary Figures S4–S7).
The top network enriched in the VitC-induced differentially
expressed genes was cell cycle, cellular assembly and orga-
nization, and DNA replication, recombination and repair
(Supplementary Figure S4). Interestingly, the glioblastoma
disease pathway was also found to be modulated by VitC
with a range of associated genes up-regulated (Supplemen-
tary Figure S5). On the other hand, 5Aza more effectively
influenced the: (i) cell morphology, cellular function and
maintenance, and carbohydrate metabolism (Supplemen-
tary Figure S6); and (ii) cancer, neurological disease, and or-
ganismal injury and abnormalities (Supplementary Figure
S7) networks. Even though there was similarity between the
5Aza- and VitC-induced differentially expressed genes and
DMRs, the differences in the enrichment of cellular func-
tions and networks indicated the extent of DNA demethy-
lation. This is likely due to differences at different targets as
a result of the different mechanisms associated with DNA
demethylation resulting from the administration of VitC or
5Aza. This, in turn, leads to differences in transcription and,
therefore, distinct responses from cellular pathways.
Validation of transcriptional changes to the DMR-
overlapping differentially expressed genes
To specifically investigate the association between the in-
tragenic DMRs and the differentially expressed genes, we
mapped the intragenic DMRs with the differentially ex-
pressed genes (FDR ≤ 0.05, absolute logFC ≥ 1). In all,
51 genes overlapped with VitC DMRs; and 27 genes over-
lapped with 5Aza DMRs. There were 18 genes common to
both lists (Table 3). However, due to the limited number of
genes, no cellular pathways were significantly enriched (P <
0.001).
The 60 DMR-overlapping differentially expressed genes
were further analysed using the Fluidigm platform to vali-
date their changes in gene expression. Fold changes (log2)
for each gene relative to the GBM cohort were used to gen-
erate the heatmap (Figure 3A; detailed results are shown in
Supplementary Table S5). Genes with their levels of expres-
sion modulated by at least one of the treatments over abso-
lute 2-fold are separately plotted in Figure 3B. The statisti-
cal significances are indicated on the sides of the plot. Over-
all, up-regulation in expression of these genes was observed
in both treated cohorts with 5Aza triggering more signif-
icant changes than VitC (Figure 3B). MYT1, MAN1C1,
PLEC, TLE3, PALM3, FAM222A, GTF2IRD1, PRDM16,
WNK2, KIF21B and PLXNA4 were up-regulated by both
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Table 3. Differentially expressed genes that were identified to overlap with DMRs. Differentially expressed genes that were mapped with DMRs in each
comparison are listed: common DMR-overlapping differentially expressed genes that were identified in both comparisons and uniquely identified DMR-
overlapping differentially expressed genes in each comparison
Comparison DMR-overlapping differentially expressed genes
GBM+5Aza vs. GBM Unique SLCO4A1; PRICKLE2; MEIS3; MAN1C1; HSD17B14; GAS6; FNDC10; FBXO17;
COL22A1;
Common TSNARE1; TLE3; SPPL2B; SMARCD3; SEC61G; RAB7B; PRDM16; PLXNA4;
PLEC; NACAD; MEST; LINC01224; FZR1; FCGBP; ELN; CLU; CCDC71L; BCL3;
GBM+VitC vs. GBM Unique ADGRB1; AGAP3; AGPAT4; ASL; ATP6V0E2-AS1; C2CD4C; C7orf57; CLIP2;
COL4A2; CYP4F11; FAM20C; FAM222A; FAM49A; GTF2IRD1; HSPG2; KIF17;
KIF21B; LRRC4B; LTBP4; LYPLA1; MASP2; MYCNUT; MYT1; NKAIN4; PALM3;
PDGFA; PRKAG2; PTPRS; SHC2; SNX10; ST3GAL1; TTYH1; WNK2;
Figure 3. The validation of gene expression using the Fluidigm array. (A) Heatmap of the gene expression levels of the DMR-overlapping differentially
expressed genes. For each gene, fold changes to the mean value of the respective gene in the GBM cohort (log2) were plotted. (B) Heatmap of the gene
expression levels of the DMR-overlapping differentially expressed genes that had more than 2-fold changes after either of the treatments. Statistical sig-
nificances are indicated at the sides of the plot relevant to each gene: the left side is for the GBM+VitC cohort and the right side is for the GBM + 5Aza
cohort. **, ***, **** indicate P values < 0.01, 0.001, 0.0001, respectively; ns = not significant. (C) Differential expression of the regulators of DNA
methylation. Bars represent the mean of the relative quantification levels in log2 scale normalized to the GBM cohort. Detailed statistical results of the
DMR-overlapping differentially expressed genes are shown in Supplementary Table S5. Bars in black represent GBM + VitC; bars in grey represent GBM
+ 5Aza. Error bars show SEM. The level of significance for each gene is labelled above each bar, **, ***, **** indicate P values < 0.01, 0.001, 0.0001,
respectively. The red hash line at 1 indicates 2-fold change of up-regulation.
GAS6 were down-regulated by both treatments by over 2-
fold, which indicates their expression levels are sensitively
modulated by DNA demethylation. Interestingly, SEC61G
encodes a subunit of the Sec61 complex as the central com-
ponent of the protein translocation apparatus of the endo-
plasmic reticulum membrane. This gene is located upstream
of another hallmark of GBM, EGFR, and is highly over-
expressed in GBM to support tumour cell survival (61).
WNK2 encodes the tumor suppressor WNK lysine defi-
cient protein kinase 2, which is regulated by DNA methy-
lation at its promoter region and loss of expression has
been found in GBM as a result of promoter hyperme-
thylation (62). PRDM16, PR domain containing 16, was
found to be overexpressed when its promoter is hypomethy-
lated and contributes to tumorigenesis by disrupting mito-
chondrial function in astrocytoma (63). Furthermore, 13
genes (ASL, LTBP4, CLU, PRKAG2, AGAP3, LYPLA1,
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and ELN) were only significantly modulated by 5Aza to
over 2-fold. They are likely to be more sensitive to the DNA
demethylation mediated by the inhibition of DNMT1 activ-
ity resulting from the 5Aza treatment (Figure 3B).
As there were different patterns of DNA methylation
and gene expression induced by 5Aza and VitC, we in-
vestigated the levels of gene expression for the regula-
tors of DNA methylation including the DNA methylation
enzymes, namely methyltransferases DNMT1/3A/3B/3L,
and the DNA demethylation enzymes, namely TET1/2/3.
It is known that 5Aza inhibits DNA methylation through
the DNMT1 enzyme, whereas VitC acts as the co-factor
of the TET1 enzyme to enhance DNA demethylation
(42,43). TET-mediated DNA demethylation converts 5mC
to 5hmC, which is important for the regulation of the
tumour- and differentiation-related genes. The DNMT3
family is known to mediate de novo DNA methylation and
is maintained by DNMT1 during DNA replication. The
expression of DNMT3L, the co-factor of DNMT3A, was
not detected in each of the three cohorts. TET3 was signif-
icantly up-regulated following treatment with VitC by >2-
fold compared with the GBM cohort (Figure 3C), whereas
5Aza enhanced the expression of DNMT3B and TET3 by
>2-fold (Figure 3C). When we compared the two DNA
demethylation agents, treatment with 5Aza resulted in sig-
nificantly higher levels of gene expression for DNMT3B
than VitC (P < 0.01; Figure 3C). VitC triggered signifi-
cantly higher levels of expression for TET1 than 5Aza (P <
0.001; Figure 3C). The up-regulation of DNMT3B is likely
to be a response to global DNA demethylation in order to
compensate for the reduced levels of DNA methylation in-
duced by the DNA demethylation agents. Indeed, this is a
typical feature, which is similar to the rebound effect when
DNA demethylation agents are withdrawn from cancer cells
and they return to their hypermethylated state (4,64). It
is also interesting to note that the levels of expression for
TET1 were up-regulated by its co-factor VitC, and not by
5Aza. The differences shown in the methylation factors fur-
ther indicated that these two treatments could mediate dif-
ferent DNA demethylation machineries as different targets
in the genome were modulated.
The changes in DNA methylation to the genomic regions of
the mtDNA transcription and replication factors
We specifically focused on investigating the changes in
DNA methylation to the genomic regions of the mtDNA
transcription and replication factors. Indeed, the rationale
for undertaking this analysis is supported by the >3-fold
increase in mtDNA copy number induced by the DNA
demethylation treatments, which strongly indicates that
mtDNA copy number is epigenetically regulated (Figure
4A) (4,32). Increased mtDNA copy number has also pre-
viously been shown to be tightly associated with the key
regulator of mtDNA replication, POLG and more specifi-
cally associated with the DNA methylation status of a CpG
island (CGI) in its second exon (4). Indeed, CGIs are ge-
nomic regions with repeated CpGs that usually exhibit low
levels of DNA methylation. However, they are more tightly
associated with regulatory roles in gene transcription than
CpG dinucleotides, which are present throughout the whole
genome (65).
To further investigate changes in DNA methylation to
the other mtDNA transcription and replication factors, the
relative methylation score of CGIs found in the gene bod-
ies and their promoter regions were analyzed using the
MEDIPS package based on the MeDIP-Seq data. A total
of 20 mtDNA transcription and replication factors were ex-
amined and had a CGI in the promoter regions of at least
one transcript variant, which indicates their expression is
highly likely to be affected by DNA methylation. Overall,
reduced levels of DNA methylation were observed in the
treated cohorts (Supplementary Figure S8). VitC signifi-
cantly reduced the levels of DNA methylation in three pro-
moter CGIs, TFB1M, TWNK and SSBP1 (Supplementary
Figure S8).
The gene-body CGIs of the mtDNA transcription and
replication factors were also analysed in the same way (Fig-
ure 4B). Firstly, the significant reduction in DNA methy-
lation at exon 2 of POLG induced by both treatments
was compatible with our previous findings (4). We also in-
vestigated the four CGIs that overlapped within intron 7,
exon 8, exon 10 and intron 10 of TOP1MT, which would
strongly indicate that the expression of TOP1MT is prob-
ably modulated by DNA methylation, as is the case for
POLG (4,6). Both treatments caused a significant decrease
in DNA methylation at exon 8 of TOP1MT, while the CGI
at intron 10 was only significantly demethylated by VitC.
CGIs at the boundary of exon 1 and intron 1 of TWNK and
intron 1, exon 2/6 of ESRRB did not undergo significant
DNA demethylation. Using MeDIP-qPCR, we confirmed
that demethylation had taken place at exon 2 of POLG and
exon 8 of TOP1MT through both 5Aza and VitC (Figure
4C). Interestingly, our validation also showed that the CGI
at intron 10 of TOP1MT was also demethylated by both
agents (Figure 4C).
These data show that the DNA methylation status at the
promoter-located CGIs and the gene-body CGIs are mod-
ulated by the DNA demethylation treatments, which prob-
ably affect the gene expression profiles of these transcrip-
tion and replication factors and their ability to regulate
mtDNA copy number. To validate this, we determined the
levels of expression of each of the transcription and replica-
tion factors. Firstly, we confirmed our previous finding that
the expression of POLG was significantly up-regulated to
∼ 2-fold in both demethylated cohorts (Figure 4D). Along
with POLG, the vast majority of the transcription and
replication factors showed increased levels of expression af-
ter the DNA demethylation treatments. NRF1, NRF2 and
STAT3 more than doubled their levels of expression after
VitC treatment (Figure 4D) and even more so after 5Aza
treatment. ESRRB, TWNK, TOP1MT, POLRMT, HIF1α
and SIRT1 were significantly increased by <2-fold by VitC
(Figure 4D). However, 5Aza increased expression for each
of these genes to >2-fold (Figure 4D). SSBP1 was down-
regulated in both cohorts, which indicates DNA demethy-
lation treatments are likely to suppress its expression (Fig-
ure 4D). IDH1, involved in the TCA cycle and associ-
ated with TET-mediated DNA demethylation, was down-
regulated by VitC by over 2-fold (Figure 4D). Interestingly,
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Figure 4. Analysis of mtDNA transcription and replication factor related regions. (A) mtDNA copy number for the three cohorts. mtDNA copy number
per cell for the GBM, GBM + VitC and GBM + 5Aza cohorts (n = 3). (B) DNA methylation levels expressed as relative methylation score (RMS) over the
CGIs located within the gene bodies of the mtDNA transcription and replication factors are shown (n = 3). The relative methylation score was determined
using the MEDIPS package based on the MeDIP-Seq data. (C) Validation for DNA methylation using MeDIP-qPCR at exon 2 of POLG, and exon 8 and
intron 10 of TOP1MT (n = 3). DNA methylation levels were determined by normalizing 5mC to the input (5mC/Input). (D) Validation for gene expression
of the mtDNA transcription and replication factors (n = 6). Statistical analysis was performed using One-way ANOVA. Bars represent the mean ± SEM.
* to **** indicate P values of < 0.05, 0.01, 0.001, 0.0001. The GBM cohort is shown by the light blue bars; the GBM + VitC cohort is shown by the purple
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for the two treatments. Their levels of expression were de-
creased after VitC treatment but slightly up-regulated by
5Aza treatment (Figure 4D). From the comparisons be-
tween the two treated cohorts, 5Aza had significantly more
effect on increasing the levels of gene expression, especially
on the direct-binding transcription and replication factors,
which included TFB1M, POLG2, TOP1MT, TWNK, POL-
RMT and POLG. The indirect transcription and replica-
tion factors, including SIRT3, PGC1α, IDH2, ESRRA,
HIF1α, SIRT1, STAT3 and NRF1, were also more greatly
affected by 5Aza than VitC (Figure 4D). Furthermore, we
analysed other tumor markers of GBM including EGFR,
BCL2, TP53, TERT, SHC2 and MYC that interact closely
with the mtDNA transcription and replication factors (66–
69). Similarly, overall up-regulation was observed after the
treatments, but only 5Aza significantly up-regulated EGFR,
BCL2 and TERT to ∼2-fold or above. However, 5Aza was
found to repress MYC by over 1.5-fold (Figure 4D).
The relationship between mtDNA methylation and the ex-
pression of mtDNA-encoded genes
In the human mitochondrial genome (hg38), there are 435
CpG dinucleotides (70). Even though DNA methylation of
mtDNA remains controversial, there is an increasing num-
ber of findings indicating that mtDNA methylation takes
place, especially in the main non-coding region, the D-
loop (70,71). Since the nuclear genome harbours mtDNA-
pseudo genes, we performed MeDIP on purified popula-
tions of mtDNA to investigate the presence of mtDNA
methylation.
Firstly, to determine the degree of nuclear DNA elimina-
tion from the purified mtDNA samples, we normalized the
levels of nDNA (-globin) to levels of mtDNA. The rela-
tive levels of nDNA in the purified mtDNA samples were
significantly lower than in the total DNA samples isolated
from cells that had not undergone mitochondrial isolation
(Figure 5A). Indeed, significant reductions of nDNA (to
nearly zero) in all three cohorts were achieved by the pu-
rification process. To determine whether mtDNA is DNA
methylated, we tested purified mtDNA and long PCR frag-
ments generated from the purified mtDNA, that had been
treated with and without a CpG methylation specific en-
zyme. In this respect, we generated two overlapping frag-
ments of mtDNA (∼8500 bp) by long PCR using primer
set 1 (Supplementary Table S1) and treated these fragments
with the CpG methylation enzyme, M.SssI to generate a
positive control (Pos-longPCR-5mC) and without the en-
zyme to generate a negative control (Neg-longPCR-5mC),
as PCR products alone do not maintain methylation. As
can be seen from Figure 5B, the purified mtDNA sample
(mtDNA-5mC) had weaker signals than the positive con-
trol (Pos-longPCR-5mC) and stronger signals than the neg-
ative control (Neg-longPCR-5mC). Additionally, no bands
were observed for the non-antibody control for MeDIP
(mtDNA-NAC), and the non-template control (NTC) in-
dicating that the mitochondrial genome can undergo DNA
methylation.
Since the purified mtDNA sample had a weaker signal
than the positive control, we performed the MeDIP as-
say (with sonication) on purified mtDNA samples and the
Pos-longPCR-5mC and the Neg-longPCR-5mC controls to
quantify the levels of DNA methylation at different regions
of the mitochondrial genome. The levels of DNA methy-
lation were determined by firstly normalizing the qPCR
signals of the MeDIP products to their corresponding in-
put samples (5mC/Input), and then weighting against the
positive and negative controls that were used to represent
100% and 0% levels of DNA methylation, respectively (Fig-
ure 5C). We assessed the non-coding regions (OH, OL, HSP
and LSP), 2 rRNAs and all 13 ETC subunits using region-
specific primers (Figure 5C; Supplementary Table S1). In
HSR-GBM1 cells, methylated mtDNA molecules represent
≤29% of the total population, and levels of DNA methy-
lation in different regions varied. When comparing all re-
gions with ND5, which was identified as having the highest
level of DNA methylation, all the other regions were sig-
nificantly lower (Figure 5C). Additionally, HSP and LSP
were higher than the replication start sites OH and OL.
DNA methylation levels at the two rRNAs were relatively
low. Amongst the ETC subunits, ND5, ND6, ND2, ATP6
and CYTB had relatively higher levels of DNA methylation
than the other ETC-encoding genes. Interestingly, follow-
ing treatment with the DNA demethylation agents, 5Aza
and VitC, there were significantly reduced levels of DNA
methylation at most of the regions except for CO3, ND1,
ND3, OL and RNR2 (Figure 5C). In contrast to the results
observed for the nuclear genome, 5Aza induced more exten-
sive DNA demethylation to the mitochondrial genome than
VitC with CO1, CO2, OH and RNR1 being only demethy-
lated by 5Aza.
As HSP and LSP are the transcription start sites of the
heavy and light strands, we therefore investigated the lev-
els of gene expression for the 13 mtDNA-encoded genes
and 2 rRNAs (Figure 5D). In contrast to the overall
up-regulation observed for nuclear gene expression, over-
all down-regulation was observed for the mitochondrial-
related genes following induction of DNA demethylation.
Through both agents, RNR2, ND3, ATP6 and CO3 were
significantly down-regulated by ∼2-fold or more. 5Aza also
triggered significant down-regulation in ATP8. However,
there was no overall correlation between gene-specific DNA
methylation and gene expression.
We also extended the scope to the chromosomal genes
encoding the ETC subunits as they are also indicative of
mitochondrial function and cellular metabolism. Through
both agents, CYC1, encoding a subunit of complex III, had
decreased levels of expression induced by both treatments,
whereas SDHC, encoding a subunit of complex II, had in-
creased levels of expression by >2-fold after 5Aza treatment
(Figure 5D). Apart from this, the difference between these
two agents reached significant levels in SDHB/C/D (encod-
ing subunits of complex II) (Figure 5D). 5Aza promoted
the expression of the tumor suppressors SDHC more than
VitC, whereas VitC repressed the expression of SDHB/D.
DISCUSSION
The replication of mtDNA is strictly regulated during dif-
ferentiation and tumorigenesis to ensure that cellular en-
ergy through OXPHOS is generated in a cell type-specific
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Figure 5. Levels of DNA demethylation in the mitochondrial genome and expression levels of the mtDNA encoded genes. (A) Detection of nDNA
contamination after mtDNA purification. Copy number for nDNA (-globin) relative to the copy number for mtDNA was plotted. Multiple t-tests were
performed between the purified mtDNA samples (gray bars) and corresponding total DNA samples (black bars) isolated from GBM cells. Bars represent
the mean ± SEM (n = 3). (B) Agarose gel showing long-PCR products from purified mtDNA samples to demonstrate the presence of mtDNA methylation.
Long PCR using two pairs of primers (primer set 2) spanning across the mitochondrial genome was performed on: (i) total DNA isolated from non-treated
GBM cells (Total DNA); (ii) the positive control - MeDIP performed on the long PCR products previously generated with primer set 1 and treated with the
M.SssI enzyme (Pos-longPCR-5mC); (iii) purified whole mtDNA having undergone MeDIP - (mtDNA-5mC); (iv) the negative control - MeDIP performed
on the long PCR products previously generated with primer set 1 (Neg-longPCR-5mC); (v) the non-antibody control for MeDIP – MeDIP was performed
on the purified mtDNA without using the 5mC antibody (mtDNA-NAC); and (vi) a non-template control (H2O) for PCR (NTC). Fragment sizes are
indicated. (C) Normalized levels of DNA methylation within regions of the mitochondrial genome determined on purified mtDNA samples that had
undergone MeDIP with sonication. The normalized levels of DNA methylation were determined by normalizing the MeDIP results (5mC/Input) against
the positive and negative controls that were used to represent 100% and 0% of DNA methylation, respectively. Statistical significance was determined
between the 5Aza and VitC treated cohorts and the GBM cohort and between ND5 and all the other genes by two-way ANOVA (n = 3). (D) Significant
differential expression of the mitochondrial and chromosomal genes encoding the ETC subunits identified in the treated and non-treated cohorts using
the Fluidigm array. Bars represent the mean of the relative quantification levels normalized to the GBM cohort (n = 6). *, **, ***, **** indicate P values
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mtDNA copy number and, thus, primarily rely on glycol-
ysis to promote their high rates of proliferation (4). HSR-
GBM1 cells are stem-like cancer cells with restricted poten-
tial to differentiate and exhibit a hypermethylated genome
(35). We have previously shown that the levels of DNA
methylation at exon 2 of POLG are negatively correlated
with mtDNA copy number in HSR-GBM1 cells to restrict
their potential to complete differentiation (4). However, in
the presence of DNA demethylation agents, such as 5Aza
and VitC, global demethylation, including demethylation
at exon 2 of POLG, promotes synchrony between mtDNA
replication and chromosomal gene expression (4). Conse-
quently, these cells are able to undergo differentiation in a
manner similar to adult stem cells. Likewise, the partial and
near complete depletion of mtDNA in cancer cells alters the
levels of DNA methylation at exon 2 of POLG and the tu-
morigenic capacity of these cells (5).
Here, we have shown that the global DMRs and dif-
ferentially expressed genes induced by DNA demethyla-
tion through 5Aza and VitC overlap greatly with associ-
ated cancer pathways, such as cell death, cell prolifera-
tion and glioblastoma, by altering the expression levels of
tumorigenic-specific genes. Both up- and down-regulation
were observed in the RNA-Seq datasets due to DNA
demethylation, which probably not only resulted from the
direct impact on the targeted genes but also from sequen-
tial responses. To this extent, we have shown that tumour
markers that overlapped with DMRs included PRDM16
and WNK2, which were up-regulated by 5Aza and VitC,
whereas the oncogene of GBM, SEC61G, was significantly
down-regulated as a result of both treatments. SEC61G is
located upstream of EGFR, which is a biomarker of GBM
(61). Indeed, PRDM16, WNK2 and SEC61G were iden-
tified as DMR-overlapping differentially expressed genes
that aligned with the pathway analysis to show the DNA
demethylation treatments primarily target cell death, cell
growth and cell differentiation in GBM.
In terms of the mtDNA-specific transcription and repli-
cation factors, the results firstly confirmed our previous
finding that, by using DNA demethylation agents, DNA
methylation levels decreased across the key regulatory re-
gion, exon 2, of POLG and, as a result, the expression
of POLG was significantly increased. In addition, we have
identified differentially methylated CGIs in the gene body
of TOP1MT, especially at exon 8 and intron 10 by both
treatments. The existence of several differentially methy-
lated CGIs in TOP1MT strongly indicates the transcrip-
tional control by DNA methylation on this gene. In-
deed, TOP1MT was found to be significantly up-regulated
by 5Aza to over 2-fold. However, TET-mediated DNA
demethylation induced by VitC also increased its gene ex-
pression but not to significant levels.
We further investigated the impact of DNA demethy-
lation on the other mtDNA transcription and replication
factors. Overall, up-regulation of expression profiles was
observed, which is likely to be the major contributor to
the up-regulation of mtDNA copy number. The transcrip-
tion and replication factors including NRF1/2 and STAT3
were up-regulated by 5Aza and VitC to over 2-fold, whilst
5Aza had greater effect in promoting 10 of the transcrip-
tion and replication factors to over 2-fold including the
direct-binding mtDNA transcription and replication fac-
tors TWNK, TOP1MT, POLRMT and POLG. Interest-
ingly, SSBP1 was down-regulated by both treatments. How-
ever, it is the gene that had the highest level of methyla-
tion for the promoter CGIs amongst the mtDNA transcrip-
tion and replication factors. Therefore, there is likely to
be other regulatory machinery offsetting the up-regulatory
role of demethylation at the promoter region of SSBP1
and causing the down-regulation of SSBP1. Furthermore,
TFB1M, SIRT3, PGC1α and SIRT3 were down-regulated
by VitC but slightly up-regulated by 5Aza. Although the
DNA demethylation levels that occurred over their pro-
moter regions were similar following the two treatments,
the opposite patterns presented for gene expression likely
resulting again from other patterns of regulation, such as
to the upstream regulators of TFB1M, which include the
NRFs and PGC1 (24), rather than from DNA demethyla-
tion to TFB1M itself.
Additionally, IDH is tightly involved in mitochondrial
function through the TCA cycle and considered to con-
tribute to the hypermethylation of many types of can-
cers including GBM (33,37–39). In the TCA cycle, mutant
IDH can alter the metabolic pathway to generate (R)-2-
hydroxyglutarate, known as an oncometabolite, instead of
-ketoglutarate (33,37,40). This metabolic change disrupts
the normal function of the TET enzymes, and results in the
hypermethylated genomes of cancers (33,37,40). Our results
showed that there was an impact of DNA demethylation on
the expression levels of IDH1 and IDH2. IDH2 could be
significantly up-regulated by 5Aza, while IDH1 was down-
regulated only by VitC. IDH1 encodes the cytosolic IDH
isoform, whereas IDH2 encodes the mitochondrial isoform
(39). Moreover, our finding also suggests that up-regulation
of the TET family after DNA demethylation treatments
compensates for or modulates DNA methylation, which
was likely contributed by the up-regulation of IDH2 in the
mitochondria. Thus, our finding suggests that the induced
DNA demethylation could interfere with the TCA cycle in
the mitochondria, and the differences in changes to gene
expression between IDH1 and IDH2 might indicate a re-
sponse to the treatments according to their different sites of
action.
Apart from the DMR-overlapping differentially ex-
pressed genes, we also analysed other tumor markers in-
cluding BCL2, TP53, EGFR, SHC2, TERT and MYC that
interact tightly with the mtDNA transcription and replica-
tion factors in GBM (66–69,73) (Figure 4D). Up-regulation
occurred in nearly all of these factors after both treatments,
amongst which EGFR, BCL2 and TERT were up-regulated
by 5Aza by over 2-fold while 5Aza repressed the expres-
sion of MYC (>1.5 fold). As an oncogene and an impor-
tant transcription factor for cell proliferation, the differ-
ent consequences of the up- or down- regulation of MYC
by VitC and 5Aza could lead to various patterns of down-
stream metabolic reactions in cancer cells (64). PGC1α, re-
pressed by MYC in cancer cells, plays vital roles in regulat-
ing mitochondrial function and metabolic features of can-
cer stem cells (66,74). Our findings show that the levels of
gene expression for PGC1α were up-regulated by 5Aza, but
not by VitC. Moreover, MYC is also reported to have a di-
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to the promoter regions of several key mtDNA transcrip-
tion and replication factors including POLG and POLG2
(75). POLG was significantly up-regulated after both DNA
demethylation treatments. These changes could result from
DNA demethylation through their direct effect on their own
specific gene expression, for example the CGI at exon 2 of
POLG, or indirectly via their upstream regulators, for ex-
ample MYC.
Even though it is thought that mtDNA is not as exten-
sively methylated as the nuclear genome, there are methy-
lated sites in mtDNA that have previously been reported
with unknown functions associated with mtDNA transcrip-
tion (59,76). Our results confirmed the existence of DNA
methylation in mtDNA by using a MeDIP assay. In general,
the level of mtDNA methylation in GBM cells was <29%
relative to the fully methylated positive control (Figure 5C).
Even though mtDNA methylation was not present at a high
level as shown by us and others (59,76), DNA demethy-
lation agents were able to take effect in the mitochon-
drial genome. DNMT and TET enzymes have been found
in mitochondria (59,77), which provide explanations as to
why VitC, the activator of TET, and 5Aza, the inhibitor
of DNMT, were able to significantly reduce the levels of
mtDNA methylation. The control region of mtDNA under-
went significant demethylation by 5Aza and VitC. The con-
trol region contains the start sites of transcription for both
strands (HSP and LSP) and the origin of replication for the
heavy strand (OH), where the mtDNA transcription and
replication factors bind to initiate transcription and repli-
cation of mtDNA (1). Significant DNA demethylation was
observed at HSP and LSP induced by both agents. 5Aza
also significantly demethylated the OH site. The methyla-
tion status of this region could potentially affect the acces-
sibility of the transcription and replication factors, similar
to events observed in the nuclear genome, where, for exam-
ple, the methylation status of exon 2 of Polg is associated
with the binding of RNA polymerase II (32). Other than the
control region, induced DNA demethylation at most of the
mitochondrial genes was observed in both treated cohorts
except for CO3, ND1, ND3, OL and RNR2.
In contrast to the negative correlation observed between
DNA demethylation and up-regulation in nuclear gene ex-
pression, the patterns of mitochondrial gene expression
showed overall down-regulation after DNA demethylation.
Indeed, the down-regulation of mtDNA expression induced
by the DNA demethylation agents is intriguing given that
there are increased numbers of mtDNA copy induced by
the DNA demethylation agents that would provide more
template for mtDNA transcription. Consequently, in the
presence of more templates, DNA demethylation repressed
the transcription of the primary polycistronic transcripts of
mtDNA. RNR2, ND3, ATP6, CO3 and ATP8 were signif-
icantly down-regulated to around 2-fold or more by both
treatments. In synchrony with this, the transcription fac-
tors TFAM and TFB1/2M were also down-regulated or re-
mained at similar levels of expression compared to the up-
regulation of the other replication factors. Therefore, one or
more factors could mediate the overall down-regulation of
mtDNA expression.
Apart from the overall down-regulation, the change in
expression for each gene varies, which led us to determine
whether there were gene-specific correlations between the
levels of DNA demethylation and transcriptional changes.
However, we did not observe any gene-specific correlations.
Gene-specific changes to mitochondrial genes that are as-
sociated with DNA methylation have been reported in p53-
knockout mouse embryonic fibroblasts (59) and diabetic
retinopathy (78). However, no validated mechanism has
been fully described. The gene-specific expression did not
result from the direct effect of DNA methylation, as it prob-
ably could only affect transcription at the level of the poly-
cistronic RNA, likely from the potential indirect effects
of DNA methylation on the post-transcriptional process.
The tRNA punctuation model has been widely proposed to
be the primary machinery of post-transcriptional process-
ing of the polycistronic transcripts in human mitochondria
(79,80). CO3, ATP6 and ATP8 are located sequentially on
the mitochondrial genome without a recurring tRNA in be-
tween, which likely explains why the changes to gene expres-
sion induced by DNA demethylation remained similar over
the three genes after processing. Indeed, whether mtDNA
methylation adds an epigenetic layer in regulating mtDNA
transcription has not been fully understood.
Whilst it has been reported that induced CpG methy-
lation by the mitochondrial targeted M.SssI enzyme de-
creased mtDNA copy number in human colon carci-
noma HCT116 cells (76,81), we have observed increases
in mtDNA copy number resulting from DNA demethyla-
tion induced by 5Aza and VitC but decreases in mtDNA
transcription. We propose that mtDNA demethylation en-
sures that the mitochondrial genome is accessible for repli-
cation through fewer CpG sites being methylated. DNA
demethylation induced by these agents also results in DNA
demethylation of key mtDNA replication factors, such as
POLG, and increases in their expression to further pro-
mote mtDNA replication. Even though mtDNA transcrip-
tion was down-regulated, the RNA-DNA hybrid primer
would appear to be available to initiate replication, as re-
cently shown (76,81). Whether transcription is by-passed or
specifically down regulated remains to be determined. How-
ever, DNA demethylation induced the two genomes to pro-
mote mtDNA replication in synchrony with altered patterns
of gene expression of the nuclear genome, which would be
indicative of a cell going through differentiation unlike ma-
ture cells that would likely have less replication and priori-
tize transcription to promote energy production (6,32). In-
deed, it is worth pointing out that there are short waves of
mtDNA replication which do not reflect the need for ATP-
derived by OXPHOS, as, for example, when mouse embry-
onic stem cells differentiate into mature cells types (2). As
with DNA demethylated GBM cells, these events could rep-
resent a checking mechanism to ensure synchrony between
the nuclear and mitochondrial genomes in order that cell
differentiation can proceed. Consequently, during differen-
tiation, it appears that mtDNA replication can take place
independently of mtDNA transcription.
The differences observed for DNA demethylation and
gene expression induced by 5Aza and VitC provide in-
sights into their different modes of action in inducing DNA
demethylation. 5Aza is an analogue of cytosine that com-
petitively binds to DNMT1 so that DNMT1 could not
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acts as the cofactor of TET1 to enhance its activity (42).
The unique DMRs and different proportions of overlap-
ping regions of the genome provide evidence of their dif-
ferent modes of actions. Based on the use of the same
methylome provided by the HSR-GBM1 cells, VitC signif-
icantly demethylated more genomic regions, especially in-
tragenic regions. However, there were DMRs uniquely reg-
ulated by both agents. There is limited knowledge as to
whether these agents have specific targets or preference over
certain genomic regions. We have shown that the induced
DNA demethylation caused by these two treatments differ-
entially regulated gene expression. Even though 5Aza in-
duced fewer DMRs compared with VitC, it affected gene
expression more effectively. Indeed, VitC has been shown to
have a faster rebound effect than 5Aza after its withdrawal,
which allows cells to return to their original states (4). It is
likely that, as HSR-GBM1 cells have fast rates of cell divi-
sion (4), the inhibition of DNMT1 by 5Aza prevented the
DNA methylation patterns in the newly formed cells from
being reestablished, and allowed the transcription factors
to bind to the genome to promote gene expression. How-
ever, the TET enzymes, enhanced by VitC, were interacting
extensively with the genome to carry out DNA demethyla-
tion but the occupancy of the TET enzymes on the genome
might result in less accessibility of the transcription factors
to promote gene expression. Additionally, we also found
several interesting differences in the effects induced by 5Aza
and VitC: (i) the changes to the expression of IDH1 and
IDH2 (discussed above); (ii) the changes to the expression
of the key regulator of mitochondrial function and tumori-
genesis, MYC, were contrasting where VitC up-regulated
MYC and 5Aza down-regulated MYC; and (iii) 5Aza in-
duced greater DNA demethylation in mtDNA than VitC,
but the changes to mtDNA expression were more signifi-
cantly modulated by VitC, which was opposite to what was
found in the nucleus.
In all, we have shown that global demethylation of the
GBM genome induces changes to several key tumor mark-
ers, such as SEC61G, PRDM16 and WNK2, and that sev-
eral key pathways including glioblastoma, cell death, cell
growth and cell differentiation are also affected as a re-
sult. We further show that increases in mtDNA copy num-
ber coincided with increases in the expression of many of
the mtDNA replication factors, two of which appear to
be modulated by DNA demethylation, namely POLG and
TOP1MT, that were identified from our mtDNA repli-
cation factor-specific screen. Furthermore, the expression
of the tumour markers EGFR, BCL2, TERT and MYC,
which interact with the mtDNA transcription and replica-
tion factors, were also modulated by the DNA demethyla-
tion agents suggesting an association between the key regu-
lators of cellular fate and mtDNA replication. These inter-
actions likely empower HSR-GBM1 cells to undergo dif-
ferentiation as we have previously shown after culture with
both 5Aza and VitC (4) and to break free from their pseudo-
differentiated state where they are trapped between two
states, an undifferentiated and a fully differentiated state
(7,8). It would, thus, appear that synchrony between nuclear
gene expression and the regulation of mtDNA copy num-
ber, and thus resetting of the mtDNA set point, are impor-
tant to cellular differentiation and that hypermethylation in
HSR-GBM1 cells impinges on this process.
DATA AVAILABILITY
MeDIP-Seq sequences in triplicates for HSR-GBM1 cells
and the cells treated with 5Aza and VitC have been de-
posited in the Sequence Read Archive (SRA) under acces-
sion number SRP080899. CNV data and RNA sequencing
data have been deposited in the Gene Expression Omnibus
(GEO) under accession number GSE98693.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
ACKNOWLEDGEMENTS
We are grateful to Dr Trevor Wilson and Dr Selva Ku-
mari Ramasubramanian, The Medical Genomics Facility
Monash Health Translation Precinct, for assistance in per-
forming next generation sequencing and the Fluidigm high-
throughput real-time PCR array, respectively. We are grate-
ful to BioDiscovery, Inc. for the use of Nexus Copy Number
software in our data analysis. We thank Dr Aidan Sudbury
from the School of Mathematical Sciences, Monash Uni-
versity for assistance with statistical analyses.
FUNDING
Hudson Institute of Medical Research Discretionary
Funds; Victorian Government’s Operational Infrastruc-
ture Support Program; Australian Postgraduate Award (to
X.S.).
Conflict of interest statement. None declared.
REFERENCES
1. Anderson,S., Bankier,A.T., Barrell,B.G., de Bruijn,M.H.,
Coulson,A.R., Drouin,J., Eperon,I.C., Nierlich,D.P., Roe,B.A.,
Sanger,F. et al. (1981) Sequence and organization of the human
mitochondrial genome. Nature, 290, 457–465.
2. Facucho-Oliveira,J.M., Alderson,J., Splikings,E.C., Egginton,S. and
St. John,J.C. (2007) Mitochondria DNA replication during
differentiation of murine embryonic stem cells. J. Cell Sci., 15,
4025–4034.
3. Facucho-Oliveira,J.M. and St John,J.C. (2009) The relationship
between pluripotency and mitochondrial DNA proliferation during
early embryo development and embryonic stem cell differentiation.
Stem Cell Rev., 5, 140–158.
4. Lee,W., Johnson,J., Gough,D.J., Donoghue,J., Cagnone,G.L.,
Vaghjiani,V., Brown,K.A., Johns,T.G. and St John,J.C. (2015)
Mitochondrial DNA copy number is regulated by DNA methylation
and demethylation of POLGA in stem and cancer cells and their
differentiated progeny. Cell Death Dis., 6, e1664.
5. Lee,W.T., Cain,J.E., Cuddihy,A., Johnson,J., Dickinson,A.,
Yeung,K.Y., Kumar,B., Johns,T.G., Watkins,D.N., Spencer,A. et al.
(2016) Mitochondrial DNA plasticity is an essential inducer of
tumorigenesis. Cell Death Discov., 2, 16016.
6. Dickinson,A., Yeung,K.Y., Donoghue,J., Baker,M.J., Kelly,R.D.,
McKenzie,M., Johns,T.G. and St John,J.C. (2013) The regulation of
mitochondrial DNA copy number in glioblastoma cells. Cell Death
Differ., 20, 1644–1653.
7. Lee,W.T. and St John,J. (2015) The control of mitochondrial DNA













E user on 26 August 2019
5994 Nucleic Acids Research, 2018, Vol. 46, No. 12
8. Sun,X. and St John,J.C. (2016) The role of the mtDNA set point in
differentiation, development and tumorigenesis. Biochem. J., 473,
2955–2971.
9. Xu,B. and Clayton,D.A. (1996) RNA-DNA hybrid formation at the
human mitochondrial heavy-strand origin ceases at replication start
sites: an implication for RNA-DNA hybrids serving as primers.
EMBO J., 15, 3135–3143.
10. Xu,B. and Clayton,D.A. (1995) A persistent RNA-DNA hybrid is
formed during transcription at a phylogenetically conserved
mitochondrial DNA sequence. Mol. Cell. Biol., 15, 580–589.
11. Tiranti,V., Savoia,A., Forti,F., D’Apolito,M.F., Centra,M.,
Rocchi,M. and Zeviani,M. (1997) Identification of the gene encoding
the human mitochondrial RNA polymerase (h-mtRPOL) by
cyberscreening of the Expressed Sequence Tags database. Hum. Mol.
Genet., 6, 615–625.
12. Fisher,R.P. and Clayton,D.A. (1985) A transcription factor required
for promoter recognition by human mitochondrial RNA polymerase.
Accurate initiation at the heavy- and light-strand promoters dissected
and reconstituted in vitro. J. Biol. Chem., 260, 11330–11338.
13. Fisher,R.P. and Clayton,D.A. (1988) Purification and
characterization of human mitochondrial transcription factor 1. Mol.
Cell. Biol., 8, 3496–3509.
14. Falkenberg,M., Gaspari,M., Rantanen,A., Trifunovic,A.,
Larsson,N.G. and Gustafsson,C.M. (2002) Mitochondrial
transcription factors B1 and B2 activate transcription of human
mtDNA. Nat. Genet., 31, 289–294.
15. Hillen,H.S., Parshin,A.V., Agaronyan,K., Morozov,Y.I., Graber,J.J.,
Chernev,A., Schwinghammer,K., Urlaub,H., Anikin,M., Cramer,P.
et al. (2017) Mechanism of transcription anti-termination in human
mitochondria. Cell, 171, 1082–1093.
16. Kasamatsu,H., Grossman,L.I., Robberson,D.L., Watson,R. and
Vinograd,J. (1974) The replication and structure of mitochondrial
DNA in animal cells. Cold Spring Harb. Symp. Quant. Biol., 38,
281–288.
17. Clayton,D.A. (1982) Replication of animal mitochondrial DNA.
Cell, 28, 693–705.
18. Carrodeguas,J.A., Theis,K., Bogenhagen,D.F. and Kisker,C. (2001)
Crystal structure and deletion analysis show that the accessory
subunit of mammalian DNA polymerase gamma, Pol gamma B,
functions as a homodimer. Mol. Cell, 7, 43–54.
19. Kaguni,L.S. and Olson,M.W. (1989) Mismatch-specific 3′––-5′
exonuclease associated with the mitochondrial DNA polymerase from
Drosophila embryos. Proc. Natl. Acad. Sci. U.S.A., 86, 6469–6473.
20. Lim,S.E., Longley,M.J. and Copeland,W.C. (1999) The mitochondrial
p55 accessory subunit of human DNA polymerase gamma enhances
DNA binding, promotes processive DNA synthesis, and confers
N-ethylmaleimide resistance. J. Biol. Chem., 274, 38197–38203.
21. Takamatsu,C., Umeda,S., Ohsato,T., Ohno,T., Abe,Y., Fukuoh,A.,
Shinagawa,H., Hamasaki,N. and Kang,D. (2002) Regulation of
mitochondrial D-loops by transcription factor A and single-stranded
DNA-binding protein. EMBO Rep., 3, 451–456.
22. Korhonen,J.A., Gaspari,M. and Falkenberg,M. (2003) TWINKLE
Has 5′ → 3′ DNA helicase activity and is specifically stimulated by
mitochondrial single-stranded DNA-binding protein. J. Biol. Chem.,
278, 48627–48632.
23. Zhang,H., Meng,L.H. and Pommier,Y. (2007) Mitochondrial
topoisomerases and alternative splicing of the human TOP1mt gene.
Biochimie, 89, 474–481.
24. Gleyzer,N., Vercauteren,K. and Scarpulla,R.C. (2005) Control of
mitochondrial transcription specificity factors (TFB1M and TFB2M)
by nuclear respiratory factors (NRF-1 and NRF-2) and PGC-1
family coactivators. Mol. Cell. Biol., 25, 1354–1366.
25. Aquilano,K., Vigilanza,P., Baldelli,S., Pagliei,B., Rotilio,G. and
Ciriolo,M.R. (2010) Peroxisome proliferator-activated receptor
gamma co-activator 1alpha (PGC-1alpha) and sirtuin 1 (SIRT1)
reside in mitochondria: possible direct function in mitochondrial
biogenesis. J. Biol. Chem., 285, 21590–21599.
26. Kong,X., Wang,R., Xue,Y., Liu,X., Zhang,H., Chen,Y., Fang,F. and
Chang,Y. (2010) Sirtuin 3, a new target of PGC-1alpha, plays an
important role in the suppression of ROS and mitochondrial
biogenesis. PLoS One, 5, e11707.
27. Weitzel,J.M., Iwen,K.A. and Seitz,H.J. (2003) Regulation of
mitochondrial biogenesis by thyroid hormone. Exp. Physiol., 88,
121–128.
28. Enriquez,J.A., Fernandez-Silva,P., Garrido-Perez,N.,
Lopez-Perez,M.J., Perez-Martos,A. and Montoya,J. (1999) Direct
regulation of mitochondrial RNA synthesis by thyroid hormone.
Mol. Cell. Biol., 19, 657–670.
29. Sato,I., Miyado,M., Miwa,Y. and Sunohara,M. (2006) Expression of
nuclear and mitochondrial thyroid hormone receptors in postnatal
rat tongue muscle. Cells Tissues Organs, 183, 195–205.
30. Casas,F., Rochard,P., Rodier,A., Cassar-Malek,I.,
Marchal-Victorion,S., Wiesner,R.J., Cabello,G. and Wrutniak,C.
(1999) A variant form of the nuclear triiodothyronine receptor
c-ErbAalpha1 plays a direct role in regulation of mitochondrial RNA
synthesis. Mol. Cell. Biol., 19, 7913–7924.
31. Fernandez-Vizarra,E., Enriquez,J.A., Perez-Martos,A., Montoya,J.
and Fernandez-Silva,P. (2008) Mitochondrial gene expression is
regulated at multiple levels and differentially in the heart and liver by
thyroid hormones. Curr. Genet., 54, 13–22.
32. Kelly,R.D., Mahmud,A., McKenzie,M., Trounce,I.A. and St
John,J.C. (2012) Mitochondrial DNA copy number is regulated in a
tissue specific manner by DNA methylation of the nuclear-encoded
DNA polymerase gamma A. Nucleic Acids Res., 40, 10124–10138.
33. Figueroa,M.E., Abdel-Wahab,O., Lu,C., Ward,P.S., Patel,J., Shih,A.,
Li,Y., Bhagwat,N., Vasanthakumar,A., Fernandez,H.F. et al. (2010)
Leukemic IDH1 and IDH2 mutations result in a hypermethylation
phenotype, disrupt TET2 function, and impair hematopoietic
differentiation. Cancer Cell, 18, 553–567.
34. Turcan,S., Rohle,D., Goenka,A., Walsh,L.A., Fang,F., Yilmaz,E.,
Campos,C., Fabius,A.W.M., Lu,C. and Ward,P.S. (2012) IDH1
mutation is sufficient to establish the glioma hypermethylator
phenotype. Nature, 483, 479–483.
35. Galli,R., Binda,E., Orfanelli,U., Cipelletti,B., Gritti,A., De Vitis,S.,
Fiocco,R., Foroni,C., Dimeco,F. and Vescovi,A. (2004) Isolation and
characterization of tumorigenic, stem-like neural precursors from
human glioblastoma. Cancer Res., 64, 7011–7021.
36. Hess,K.R., Broglio,K.R. and Bondy,M.L. (2004) Adult glioma
incidence trends in the United States, 1977–2000. Cancer, 101,
2293–2299.
37. Turcan,S., Rohle,D., Goenka,A., Walsh,L.A., Fang,F., Yilmaz,E.,
Campos,C., Fabius,A.W., Lu,C., Ward,P.S. et al. (2012) IDH1
mutation is sufficient to establish the glioma hypermethylator
phenotype. Nature, 483, 479–483.
38. Yan,H., Parsons,D.W., Jin,G., McLendon,R., Rasheed,B.A.,
Yuan,W., Kos,I., Batinic-Haberle,I., Jones,S., Riggins,G.J. et al.
(2009) IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med., 360,
765–773.
39. Cohen,A.L., Holmen,S.L. and Colman,H. (2013) IDH1 and IDH2
mutations in gliomas. Curr. Neurol. Neurosci. Rep., 13, 345.
40. Haseeb,A., Makki,M.S. and Haqqi,T.M. (2014) Modulation of
ten-eleven translocation 1 (TET1), Isocitrate Dehydrogenase (IDH)
expression, alpha-Ketoglutarate (alpha-KG), and DNA
hydroxymethylation levels by interleukin-1beta in primary human
chondrocytes. J. Biol. Chem., 289, 6877–6885.
41. Marie,S.K. and Shinjo,S.M. (2011) Metabolism and brain cancer.
Clinics (Sao Paulo), 66(Suppl. 1), 33–43.
42. Blaschke,K., Ebata,K.T., Karimi,M.M., Zepeda-Martinez,J.A.,
Goyal,P., Mahapatra,S., Tam,A., Laird,D.J., Hirst,M., Rao,A. et al.
(2013) Vitamin[thinsp]C induces Tet-dependent DNA demethylation
and a blastocyst-like state in ES cells. Nature, 500, 222–226.
43. Jones,P.A. and Taylor,S.M. (1980) Cellular differentiation, cytidine
analogs and DNA methylation. Cell, 20, 85–93.
44. Kaminskas,E., Farrell,A.T., Wang,Y.C., Sridhara,R. and Pazdur,R.
(2005) FDA drug approval summary: azacitidine (5-azacytidine,
Vidaza) for injectable suspension. Oncologist, 10, 176–182.
45. Kelly,T.K., De Carvalho,D.D. and Jones,P.A. (2010) Epigenetic
modifications as therapeutic targets. Nat. Biotechnol., 28, 1069–1078.
46. Guo,F., Li,X., Liang,D., Li,T., Zhu,P., Guo,H., Wu,X., Wen,L.,
Gu,T.P., Hu,B. et al. (2014) Active and passive demethylation of male
and female pronuclear DNA in the mammalian zygote. Cell Stem
Cell, 15, 447–459.
47. Brunner,A.L., Johnson,D.S., Kim,S.W., Valouev,A., Reddy,T.E.,
Neff,N.F., Anton,E., Medina,C., Nguyen,L., Chiao,E. et al. (2009)
Distinct DNA methylation patterns characterize differentiated
human embryonic stem cells and developing human fetal liver.












E user on 26 August 2019
Nucleic Acids Research, 2018, Vol. 46, No. 12 5995
48. Weber,M., Davies,J.J., Wittig,D., Oakeley,E.J., Haase,M., Lam,W.L.
and Schubeler,D. (2005) Chromosome-wide and promoter-specific
analyses identify sites of differential DNA methylation in normal and
transformed human cells. Nat. Genet., 37, 853–862.
49. Li,H. and Durbin,R. (2009) Fast and accurate short read alignment
with Burrows-Wheeler transform. Bioinformatics, 25, 1754–1760.
50. Chavez,L., Jozefczuk,J., Grimm,C., Dietrich,J., Timmermann,B.,
Lehrach,H., Herwig,R. and Adjaye,J. (2010) Computational analysis
of genome-wide DNA methylation during the differentiation of
human embryonic stem cells along the endodermal lineage. Genome
Res., 20, 1441–1450.
51. Lienhard,M., Grimm,C., Morkel,M., Herwig,R. and Chavez,L.
(2014) MEDIPS: genome-wide differential coverage analysis of
sequencing data derived from DNA enrichment experiments.
Bioinformatics, 30, 284–286.
52. Yu,G., Wang,L.G. and He,Q.Y. (2015) ChIPseeker: an
R/Bioconductor package for ChIP peak annotation, comparison and
visualization. Bioinformatics, 31, 2382–2383.
53. Dobin,A., Davis,C.A., Schlesinger,F., Drenkow,J., Zaleski,C., Jha,S.,
Batut,P., Chaisson,M. and Gingeras,T.R. (2013) STAR: ultrafast
universal RNA-seq aligner. Bioinformatics, 29, 15–21.
54. Liao,Y., Smyth,G.K. and Shi,W. (2013) The Subread aligner: fast,
accurate and scalable read mapping by seed-and-vote. Nucleic Acids
Res., 41, e108.
55. Robinson,M.D., McCarthy,D.J. and Smyth,G.K. (2010) edgeR: a
Bioconductor package for differential expression analysis of digital
gene expression data. Bioinformatics, 26, 139–140.
56. McCarthy,D.J., Chen,Y. and Smyth,G.K. (2012) Differential
expression analysis of multifactor RNA-Seq experiments with respect
to biological variation. Nucleic Acids Res., 40, 4288–4297.
57. Dvinge,H. and Bertone,P. (2009) HTqPCR: high-throughput analysis
and visualization of quantitative real-time PCR data in R.
Bioinformatics, 25, 3325–3326.
58. Valente,V., Teixeira,S.A., Neder,L., Okamoto,O.K.,
Oba-Shinjo,S.M., Marie,S.K., Scrideli,C.A., Paco-Larson,M.L. and
Carlotti,C.G. Jr (2014) Selection of suitable housekeeping genes for
expression analysis in glioblastoma using quantitative RT-PCR. Ann.
Neurosci., 21, 62–63.
59. Shock,L.S., Thakkar,P.V., Peterson,E.J., Moran,R.G. and
Taylor,S.M. (2011) DNA methyltransferase 1, cytosine methylation,
and cytosine hydroxymethylation in mammalian mitochondria. Proc.
Natl. Acad. Sci. U.S.A., 108, 3630–3635.
60. Robinson,M.D., Stirzaker,C., Statham,A.L., Coolen,M.W.,
Song,J.Z., Nair,S.S., Strbenac,D., Speed,T.P. and Clark,S.J. (2010)
Evaluation of affinity-based genome-wide DNA methylation data:
effects of CpG density, amplification bias, and copy number
variation. Genome Res., 20, 1719–1729.
61. Lu,Z., Zhou,L., Killela,P., Rasheed,A.B., Di,C., Poe,W.E.,
McLendon,R.E., Bigner,D.D., Nicchitta,C. and Yan,H. (2009)
Glioblastoma proto-oncogene SEC61gamma is required for tumor
cell survival and response to endoplasmic reticulum stress. Cancer
Res., 69, 9105–9111.
62. Moniz,S., Martinho,O., Pinto,F., Sousa,B., Loureiro,C.,
Oliveira,M.J., Moita,L.F., Honavar,M., Pinheiro,C., Pires,M. et al.
(2013) Loss of WNK2 expression by promoter gene methylation
occurs in adult gliomas and triggers Rac1-mediated tumour cell
invasiveness. Hum. Mol. Genet., 22, 84–95.
63. Lei,Q., Liu,X., Fu,H., Sun,Y., Wang,L., Xu,G., Wang,W., Yu,Z.,
Liu,C., Li,P. et al. (2016) miR-101 reverses hypomethylation of the
PRDM16 promoter to disrupt mitochondrial function in
astrocytoma cells. Oncotarget, 7, 5007–5022.
64. Yang,X., Han,H., De Carvalho,D.D., Lay,F.D., Jones,P.A. and
Liang,G. (2014) Gene body methylation can alter gene expression and
is a therapeutic target in cancer. Cancer Cell, 26, 577–590.
65. Deaton,A.M. and Bird,A. (2011) CpG islands and the regulation of
transcription. Genes Dev., 25, 1010–1022.
66. Morrish,F. and Hockenbery,D. (2014) MYC and mitochondrial
biogenesis. Cold Spring Harb. Perspect. Med., 4, a014225.
67. Sahin,E., Colla,S., Liesa,M., Moslehi,J., Muller,F.L., Guo,M.,
Cooper,M., Kotton,D., Fabian,A.J., Walkey,C. et al. (2011) Telomere
dysfunction induces metabolic and mitochondrial compromise.
Nature, 470, 359–365.
68. Autret,A. and Martin,S.J. (2009) Emerging role for members of the
Bcl-2 family in mitochondrial morphogenesis. Mol. Cell, 36, 355–363.
69. Suen,D.F., Norris,K.L. and Youle,R.J. (2008) Mitochondrial
dynamics and apoptosis. Genes Dev., 22, 1577–1590.
70. Liu,B., Du,Q., Chen,L., Fu,G., Li,S., Fu,L., Zhang,X., Ma,C. and
Bin,C. (2016) CpG methylation patterns of human mitochondrial
DNA. Sci. Rep., 6, 23421.
71. Mposhi,A., Van der Wijst,M.G., Faber,K.N. and Rots,M.G. (2017)
Regulation of mitochondrial gene expression, the epigenetic enigma.
Front. Biosci. (Landmark Ed), 22, 1099–1113.
72. Kelly,R.D., Rodda,A.E., Dickinson,A., Mahmud,A., Nefzger,C.M.,
Lee,W., Forsythe,J.S., Polo,J.M., Trounce,I.A., McKenzie,M. et al.
(2013) Mitochondrial DNA haplotypes define gene expression
patterns in pluripotent and differentiating embryonic stem cells. Stem
Cells, 31, 703–716.
73. Taylor,T.E., Furnari,F.B. and Cavenee,W.K. (2012) Targeting EGFR
for treatment of glioblastoma: molecular basis to overcome
resistance. Curr. Cancer Drug Targets, 12, 197–209.
74. Sancho,P., Burgos-Ramos,E., Tavera,A., Kheir,T., Jagust,P.,
Schoenhals,M., Barneda,D., Sellers,K., Campos-Olivas,R. and
Graña,O. (2015) MYC/PGC-1 balance determines the metabolic
phenotype and plasticity of pancreatic cancer stem cells. Cell Metab.,
22, 590–605.
75. Kim,J., Lee,J.H. and Iyer,V.R. (2008) Global identification of Myc
target genes reveals its direct role in mitochondrial biogenesis and its
E-box usage in vivo. PLoS One, 3, e1798.
76. Bellizzi,D., D’Aquila,P., Scafone,T., Giordano,M., Riso,V., Riccio,A.
and Passarino,G. (2013) The control region of mitochondrial DNA
shows an unusual CpG and non-CpG methylation pattern. DNA
Res., 20, 537–547.
77. Dzitoyeva,S., Chen,H. and Manev,H. (2012) Effect of aging on
5-hydroxymethylcytosine in brain mitochondria. Neurobiol. Aging,
33, 2881–2891.
78. Mishra,M. and Kowluru,R.A. (2015) Epigenetic modification of
mitochondrial DNA in the development of diabetic retinopathy.
Invest. Ophthalmol. Vis. Sci., 56, 5133–5142.
79. Ojala,D., Montoya,J. and Attardi,G. (1981) tRNA punctuation model
of RNA processing in human mitochondria. Nature, 290, 470–474.
80. Mercer,T.R., Neph,S., Dinger,M.E., Crawford,J., Smith,M.A.,
Shearwood,A.M., Haugen,E., Bracken,C.P., Rackham,O.,
Stamatoyannopoulos,J.A. et al. (2011) The human mitochondrial
transcriptome. Cell, 146, 645–658.
81. van der Wijst,M.G., van Tilburg,A.Y., Ruiters,M.H. and Rots,M.G.
(2017) Experimental mitochondria-targeted DNA methylation
identifies GpC methylation, not CpG methylation, as potential












E user on 26 August 2019
